-
公开(公告)号:US07105653B2
公开(公告)日:2006-09-12
申请号:US10826809
申请日:2004-04-17
摘要: The invention is directed to a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
摘要翻译: 本发明涉及包含根据野生型IL-2编号的人IL-2突变蛋白的多肽,其中所述人IL-2在20,88或126位中的至少一个被取代,其中所述突变蛋白优先激活T 细胞在NK细胞上。 D20H和I,N88G,I和R特别具有比天然IL-2大得多的相对T细胞差异活性,预测相关的体内毒性降低。 本发明还包括编码本发明的突变蛋白的多核苷酸,含有多核苷酸的载体,转化的宿主细胞,包含突变蛋白的药物组合物和治疗方法。
-
公开(公告)号:US5654407A
公开(公告)日:1997-08-05
申请号:US435246
申请日:1995-05-05
申请人: Petra Boyle , Gayle D. Wetzel , Kenneth J. Lembach
发明人: Petra Boyle , Gayle D. Wetzel , Kenneth J. Lembach
IPC分类号: A61K39/395 , A61K38/00 , A61P43/00 , C07K16/24 , C12P21/08
CPC分类号: C07K16/241 , A61K38/00 , C07K2317/73
摘要: Human monoclonal antibodies (mAbs) which bind to human TNF.alpha. are disclosed. Autoantibodies of both the IgM and IgG isotypes are disclosed. A preferred human monoclonal antibody is known as B5 (F78-1A10-B5 mAb) and it binds to recombinant human TNF.alpha. (rhTNF.alpha.) in ELISA format with a titer comparable to three high affinity neutralizing mouse mAbs. It also binds to cell surface TNF.alpha. and prevents TNF.alpha. secretion by human monocyte cell lines.
摘要翻译: 公开了结合人TNFα的人单克隆抗体(mAb)。 公开了IgM和IgG同种型的自身抗体。 优选的人单克隆抗体被称为B5(F78-1A10-B5mAb),并以ELISA形式与重组人TNFα(rhTNFα)结合,其滴度与三种高亲和力中和小鼠mAb相当。 它还结合细胞表面TNFα并预防人单核细胞细胞系的TNFα分泌。
-
公开(公告)号:US06955807B1
公开(公告)日:2005-10-18
申请号:US09341351
申请日:1999-05-13
摘要: The invention is directed to a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
摘要翻译: 本发明涉及包含根据野生型IL-2编号的人IL-2突变蛋白的多肽,其中所述人IL-2在20,88或126位中的至少一个被取代,其中所述突变蛋白优先激活T 细胞在NK细胞上。 D20H和I,N88G,I和R特别具有比天然IL-2大得多的相对T细胞差异活性,预测相关的体内毒性降低。 本发明还包括编码本发明的突变蛋白的多核苷酸,含有多核苷酸的载体,转化的宿主细胞,包含突变蛋白的药物组合物和治疗方法。
-
-